Talk:Aliskiren

This is the talk page for discussing improvements to the Aliskiren article.
This is not a forum for general discussion of the article's subject.

Put new text under old text. Click here to start a new topic.
New to Wikipedia? Welcome! Learn to edit; get help.

Article policies

Find medical sources: Source guidelines · PubMed · Cochrane · DOAJ · Gale · OpenMD · ScienceDirect · Springer · Trip · Wiley · TWL

Ideal sources for Wikipedia's health content are defined in the guideline Wikipedia:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about Aliskiren.

PubMed provides review articles from the past five years (limit to free review articles)
The TRIP database provides clinical publications about evidence-based medicine.
Other potential sources include: Centre for Reviews and Dissemination and CDC

Pharmacology High‑importance

	This article is within the scope of WikiProject Pharmacology, a collaborative effort to improve the coverage of Pharmacology on Wikipedia. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.PharmacologyWikipedia:WikiProject PharmacologyTemplate:WikiProject Pharmacologypharmacology articles
High	This article has been rated as High-importance on the project's importance scale.

Medicine High‑importance

	Medicine portal This article is within the scope of WikiProject Medicine, which recommends that medicine-related articles follow the Manual of Style for medicine-related articles and that biomedical information in any article use high-quality medical sources. Please visit the project page for details or ask questions at Wikipedia talk:WikiProject Medicine.MedicineWikipedia:WikiProject MedicineTemplate:WikiProject Medicinemedicine articles
High	This article has been rated as High-importance on the project's importance scale.

External links modified

Hello fellow Wikipedians,

I have just modified one external link on Aliskiren. Please take a moment to review my edit. If you have any questions, or need the bot to ignore the links, or the page altogether, please visit this simple FaQ for additional information. I made the following changes:

Added archive https://web.archive.org/web/20110720003849/http://www.pharma.us.novartis.com/product/pi/pdf/tekturna.pdf to http://www.pharma.us.novartis.com/product/pi/pdf/tekturna.pdf

When you have finished reviewing my changes, you may follow the instructions on the template below to fix any issues with the URLs.

This message was posted before February 2018. After February 2018, "External links modified" talk page sections are no longer generated or monitored by InternetArchiveBot. No special action is required regarding these talk page notices, other than regular verification using the archive tool instructions below. Editors have permission to delete these "External links modified" talk page sections if they want to de-clutter talk pages, but see the RfC before doing mass systematic removals. This message is updated dynamically through the template {{source check}} (last update: 5 June 2024).

If you have discovered URLs which were erroneously considered dead by the bot, you can report them with this tool.
If you found an error with any archives or the URLs themselves, you can fix them with this tool.

Cheers.—InternetArchiveBot (Report bug) 12:18, 21 September 2017 (UTC)[reply]

Chemistry

The hydroxyl group of aliskiren forms hydrogen bonds with both oxygen atoms of Asp32. The amine group forms hydrogen bonds with Gly217's carboxylic acid group and Asp32's oxygen atom. The aromatic ring's methoxy group fills the S3 pocket, potentially forming a hydrogen bond with Tyr14's secondary amine. Aliskiren’s amide group forms a hydrogen bond with Ser76's secondary amine. Additionally, aliskiren selectively binds to the S3sp sub-pocket, contributing to its specificity as a renin inhibitor. The binding is stabilized by these hydrogen bonds, showcasing the specificity and potency of aliskiren as a renin inhibitor. Angeliki Giorgalli (talk) 16:06, 25 February 2024 (UTC)[reply]

Basic Pharmacokinetics

Aliskiren, a hydrophilic renin inhibitor (logP= 2.45), displays exceptional selectivity and high aqueous solubility(>350 mg/ml), with favourable pharmacokinetics supporting once-daily dosing. Metabolism occurs via CYP3A4, and despite low oral bioavailability (2.5%), its extensive tissue uptake and limited interactions make it a promising antihypertensive drug. (Vd= 135 L) Aliskiren’s main route of elimination is via faeces, supported by a study which detected radio-labeled aliskiren showing more than 80% was found in faeces. Angeliki Giorgalli (talk) 16:08, 25 February 2024 (UTC)[reply]